A Study on Assessment of Clinical, Radiological Parameters in Women Suffering from PCOD
Background: PCOS patients who fail to respond to CC are considered as clomiphene resistant. Approximately 15%–40% of women with PCOS, it is very common. Obesity, insulin resistance, ( 50%–70% of females with PCOS) and hyperandrogenemia are some major factors which postulated for CC resistance.
Methods: In this study 50 females were included on the basis of inclusion and exclusion criteria. The duration of study was over a period of 3 month. This study was conducted in the Department of Gynecology, K M Medical College & Hospital, Mathura
Result: This result revealed that 56% cases had elevated LH, 36% had hypothyroidism followed by 16% hyperprolactinemia & 4% hypoprolactinemia.
Conclusion: This study suggested that, Obesity and overweight are the most important modifiable risk factor which causes 70% of cases to prevent PCOS, weight reduction is one of the most important step.
2. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685-97.
3. Atiomo WU, El-Mahdi E, Hardiman P. Familial associations in women with polycystic ovary syndrome. Fertil Steril2003;80:143-5.
4. Radosh L. Drug treatments for polycystic ovary syndrome. Am Fam Physician 2009;79:671-6.
5. National Institute for Health and Clinical Excellence: Guidance. In: Fertility: Assessment and Treatment for People with Fertility Problems. London (UK): National Institute for Health and Clinical Excellence: Guidance; 2004.
6. Parsanezhad ME, Alborzi S, Zarei A, Dehbashi S, Omrani G. Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin. Int J Gynaecol Obstet 2001;75:43-50.
7. Overbeek A, Kuijper EA, Hendriks ML, Blankenstein MA, Ketel IJ, Twisk JW, et al. Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome. Hum Reprod2009;24:2007-13.
8. Sohrevardi SM, Nosouhi F, Hossein Khalilzade S, Kafaie P, Karimi-Zarchi M, Halvaei I, et al. Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT. Int J Reprod Biomed (Yazd) 2016;14:743-54.
9. Ayaz A, Alwan Y, Farooq MU. Metformin-clomiphene citrate vs. clomiphene citrate alone: Polycystic ovarian syndrome. J Hum Reprod Sci 2013;6:15-8.
10. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril 2009;91:456-88.
11. Balen A, Conway G, Klatas G et al. Polycystics ovary syndrome: the spectrum of the disorder in 1741 patients. Human Reproduction 1995; 10: 2107 - 2111.
12. Franks ,S.Adams J & Polson DW Prevalence of Polycystics Ovaries in women with anovulation and idiopathic hirsutism. BMJ 1986; 293: 355-359.
13. Turhan NO, Toppare MF, Seckin NC, Dilmen G. The predictive power of endocrine tests for the diagnosis of polycystic ovaries in women with oligoamenorrhea. Gynecol Obstet Invest 1999;48:183–6.
14. Aarti Sharma and William Atiomo. Recent development in polycystic ovary syndrome. Current Obstetrics & Gynaecology (2003) 13, 281 – 286.
Copyright (c) 2019 Ravi Gupta, Dhan Singh Sinsinwar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.